Emerging Evidence Suggests Semaglutide’s Role in Reducing Cardiovascular Risk

Recent studies indicate that semaglutide, a drug initially developed for diabetes and obesity, may offer important benefits in preventing cardiovascular events.This development could represent a major advancement in managing heart health, especially for individuals at high risk.

Landmark Studies Highlight Cardiovascular Benefits

Two large-scale international studies, encompassing over 35,000 participants, have provided compelling evidence of semaglutide’s cardioprotective effects. These studies,presented at the American College of Cardiology (ACC) Congress,have sparked considerable interest within the medical community.

Oral Semaglutide Reduces Cardiovascular Events in Type 2 Diabetes Patients

The SOUL (Semaglutide and Outcomes in patients with type 2 diabetes, cardiovascular disease and chronic kidney disease) trial, published in the New England Journal of Medicine, demonstrated that oral semaglutide reduced the combined risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and existing cardiovascular disease or chronic kidney disease. This multicenter international study involved 9,650 participants followed for five years.

The cardiovascular protection effect is clear, the use of the semaglutide -based pill improves heart health and vases and prevents the progression of the atherosclerosis. It has a higher efficacy than any other oral therapy also in the reduction of the values of glycated hemoglobin and in the decrease in body weight, and all this translates into a considerable protective action on the cardiovascular system.
Pasquale Perrone Filardi,president of the Italian Cardiology Society (Sic)

This finding is particularly significant given that,according to the American Heart association,adults with diabetes are two to four times more likely to die from heart disease than adults without diabetes.

Injectable Semaglutide Shows Promise in Overweight and Obese Individuals Without Diabetes

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with overweight or obesity) trial, involving 27,963 overweight or obese adults without type 2 diabetes but with established cardiovascular disease, revealed that injectable semaglutide (2.4 mg) reduced the risk of heart attack, stroke, and cardiovascular death by a remarkable 57% over an average follow-up period of approximately seven months. Furthermore, the study observed a 45% reduction when considering the combined risk of heart attack, stroke, death, hospitalization, or revascularization procedures.

Implications for Clinical Practice and Future Directions

These findings have prompted requests to regulatory bodies like the FDA and EMA for an extension of semaglutide’s approved indications to include cardiovascular risk reduction. The potential impact on public health could be substantial, considering the global prevalence of cardiovascular disease.

We must keep in mind that one person with diabetes in three also has a cardiovascular disease, therefore it is crucial to have therapies that can affect both conditions.The mechanism of action and the effects of oral trafficlutide make this treatment the standard Gold to intervene promptly on the reduction of cardiovascular risk in people with type 2 diabetes.
Ciro Dollofi, president of the Italian Federation of cardiology (FIC)

further research is warranted to fully elucidate the mechanisms underlying semaglutide’s cardioprotective effects and to determine its long-term safety and efficacy in diverse populations. However, the current evidence suggests that semaglutide could become a valuable tool in the fight against cardiovascular disease, a leading cause of death worldwide.